Provided by Tiger Fintech (Singapore) Pte. Ltd.

Park Hotels & Resorts Inc.

11.17
-0.0301-0.27%
Volume:44.97K
Turnover:502.67K
Market Cap:2.23B
PE:18.33
High:11.21
Open:11.18
Low:11.15
Close:11.20
Loading ...

IIPR's Q4 Earnings Coming Up: Key Factors to Impact the Stock

Zacks
·
18 Feb

Park Hotels & Resorts Is Maintained at Equal-Weight by Wells Fargo

Dow Jones
·
18 Feb

ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting

GlobeNewswire
·
18 Feb

RANI: Impressive Bioavailability for RT-116

Zacks Small Cap Research
·
18 Feb

Park Hotels & Resorts Inc expected to post earnings of 6 cents a share - Earnings Preview

Reuters
·
18 Feb

Park Hotels & Resorts (PK) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Zacks
·
17 Feb

Park Hotels & Resorts Inc. (PK): Among the Best Hotel Stocks to Buy According to Analysts

Insider Monkey
·
17 Feb

Press Release: Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates

Dow Jones
·
14 Feb

Agios Pharmaceuticals Reveals Encouraging Data From Rare Blood Disorder Study In Younger Patients Aged Below 18 Years

Benzinga
·
14 Feb

Press Release: Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Dow Jones
·
13 Feb

Agios’ Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint

GlobeNewswire
·
13 Feb

Actinogen announces peer-reviewed clinical pharmacology manuscript for Xanamem (emestedastat) published in Clinical Pharmacology in Drug Development journal

PR Newswire
·
12 Feb

Aptose’s Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY Trial

GlobeNewswire
·
12 Feb

Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting

GlobeNewswire
·
12 Feb

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

GlobeNewswire
·
12 Feb

Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis

GlobeNewswire
·
10 Feb

Zacks Market Edge Highlights: WASH, SPG PAA, PK and ETD

Zacks
·
10 Feb

5 Top Stocks Paying Big Dividends

Zacks
·
08 Feb

TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial

PR Newswire
·
06 Feb

Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

GlobeNewswire
·
06 Feb